Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26.
HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20 million from strategic partner Medtronic and additional investments by life sciences fund RTW.
Health Sciences 2 had about $67.7 million in its trust going into the vote after seeing 57.7% of shares redeemed in an earlier extension. Proceeds nonetheless exceeded the the transaction’s $60 million minimum cash condition.
The combined company will commence trading today on the Nasdaq under the symbol “OBIO”. Health Sciences 2 did not include warrants in its units when it IPO’d in August 2020.
The parties announced their $158 million deal with Orchestra BioMed in July 2022. New Hope, Pennsylvania-based Orchestra BioMed develops evidence-based therapeutic solutions for medical procedures that address major medical conditions, with a particular focus on cardiovascular diseases.
ADVISORS
- Jefferies LLC and Piper Sandler & Co. acted as Joint Lead Placement Agents for the Series D Financing
- Aegis Capital acted as Selling Agent.
- Jefferies LLC is acting as lead financial advisor and a capital markets advisor to Orchestra BioMed.
- Piper Sandler & Co. is acting as strategic advisor to Orchestra BioMed
- Piper Sandler & Co. is acting as a capital markets advisor to Orchestra BioMed.
- Chardan Capital Markets LLC is serving as financial and capital markets advisor to HSAC2
- Barclays Capital Inc. is serving as financial and capital markets advisor to HSAC2.
- Paul Hastings LLP is serving as legal counsel for Orchestra BioMed. Loeb & Loeb LLP is serving as legal counsel for HSAC2.
At the SPAC of Dawn The Fed’s surprisingly aggressive decision to cut rates by 50 basis points yesterday gave a big boost to several SPACs and de-SPACs, many of which had endured a long slump while uncertainty over the coming interest rate climate reigned. None had a better day on paper than digital transformation firm...
Roman DBDR II (NASDAQ:DRDB) has filed for a $200 million SPAC with serial sponsor terms just as the team’s first deal undergoes a transition with other SPAC personalities. This new vehicle has its trust overfunded to 100.5% with $10.05 per share in trust out the gate. It also has 1/2 warrants in its units with...
At the SPAC of Dawn Christmas Day has finally arrived for SPAC watchers pining for a rate cut. The only question is how many basis point presents will they find under the tree when Fed Chair Jerome Powell takes the podium at 2 pm ET today. This is far from the only economic indicator set...
YHN Acquisition I Limited announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “YHNAU”, Wednesday, September 18, 2024. The new SPAC’s search will not be limited to a particular industry or geographic location, but the sponsors intend to target companies with a...
Chenghe II (NYSE:CHEB) has entered into a definitive agreement to combine with the Polibeli Group at a $3.6 billion equity value. Jakarta-based Polibeli operates an online and app-based wholesale marketplace for small businesses on Indonesia’s Java island. The combined company is expected to trade on the NYSE once the deal is completed. Transaction Overview Chenghe...